News | December 07, 2012

SFA Stents Show Acceptable Long Term Patency

December 7, 2012 — More than half of patients treated for claudication or critical limb ischemia (CLI) with stenting of the superficial femoral artery (SFA) had primary patency at five years.

“Stenting of the SFA is associated with an acceptable success rate even after five years and in patients with long SFA lesions,” noted Giovanni Torsello, M.D., at the 39th annual VEITHsymposium.

Primary patency rates for 517 patients were, respectively, 86 percent, 75 percent and 61 percent at one, three and five years. Primary patency was defined as the absence of hemodynamically-significant stenosis on duplex ultrasound imaging (systolic velocity ratio <2.4) at the target lesion and without target lesion revascularization (TLR). There were no significant difference between TASC A/B and TASC C/D lesions groups or between bare-metal stents and drug-eluting, said Torsello, who is the chief of the department of vascular surgery at St. Franziskus-Hospital in Münster, Germany.

The results come from a retrospective review of 517 patients who reached a follow-up of at least 2 years. Overall 827 stents were implanted in 543 limbs.

More than three quarters of patients (77.9 percent) were treated for claudication, and the remaining patients were treated for CLI. TASC II C or D lesions were seen in 35.5 percent of patients, based on angiography. Complete occlusion in was seen in 42.7 percent and 13.8 percent had popliteal involvement. The average lesion length was 154.2 ±94.0 mm. After a mean follow-up of 93.4 ±1.6 months, 18.8 percent of patients died.  Mean ankle-brachial index increased from 0.67 ±0.17 to 0.98±1.7 at follow up (p<0.001). TLR was performed in 27.8 percent of the limbs treated. In addition, secondary patency rates were 95 percent, 90 percent and 76 percent after one, three and five years. Eight patients (1.5 percent) underwent major amputation.

For more information: www.veithpress.org

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init